Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

VEGFR3/Flt-4 Antibody (9D9), HRP, Novus Biologicals™
SDP

Catalog No. NB205180 Shop All R&D Systems Products
Change view
Click to view available options
Quantity:
0.1 mL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
NB205180 0.1 mL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. NB205180 Supplier Novus Biologicals Supplier No. NBP118651H
Add to Cart
Add to Cart

Mouse Monoclonal Antibody

VEGFR3/Flt-4 Monoclonal antibody specifically detects VEGFR3/Flt-4 in Human samples. It is validated for Western Blot, ELISA, Immunohistochemistry

Specifications

Antigen VEGFR3/Flt-4
Applications Western Blot, ELISA, Immunohistochemistry
Classification Monoclonal
Clone 9D9
Conjugate HRP
Formulation PBS
Gene Alias EC 2.7.10, EC 2.7.10.1, FLT-4, fms-related tyrosine kinase 4, LMPH1A, PCLFLT41, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, Tyrosine-protein kinase receptor FLT4, vascular endothelial growth factor receptor 3, VEGFR-3, VEGFR3Fms-like tyrosine kinase 4
Host Species Mouse
Immunogen Recombinant human soluble VEGFR-3/FLT-4
Purification Method Protein A purified
Quantity 0.1 mL
Regulatory Status RUO
Research Discipline Angiogenesis, Cancer, Hypoxia, Protein Kinase
Primary or Secondary Primary
Gene ID (Entrez) 2324
Target Species Human
Content And Storage Store at 4°C in the dark.
Form Purified
Isotype IgG1
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.